clinical trial · NCT07008378
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Genentech, Inc.·phase1·active not recruiting·n = 60
Multiple SclerosisP-CD19CD20-ALLO1 CellsCyclophosphamideFludarabine
brief summary
This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).
started
Oct 15, 2025
primary completion
Aug 31, 2032
completion
Aug 31, 2032
last updated
Apr 21, 2026
official title
A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol